肿瘤治疗相关心功能不全的防治

Prevention of cancer therapeutics-related cardiac dysfunction

关键词:  肿瘤心脏病学  肿瘤治疗相关心功能不全  初级预防  心脏保护  心肌标志物

Key words:  cardio-oncology  CTCRD  prevention  cardioprotection  biomarkers

摘要:

近年来，抗肿瘤药物飞速发展，肿瘤患者生存率不断提高，预防心血管毒副作用是抗肿瘤药物研究的重点。抗肿瘤药物临床试验中往往低估"现实世界"人群发生心血管事件的可能性。大量的生物标志物和影像学检查为肿瘤心脏病学家提供了有效的方法监测抗肿瘤药物心血管毒性。最佳的预防策略仍然没有达成共识，但早期诊断和干预可减少晚期心脏毒性和心脏相关事件。本文概述了最新的肿瘤治疗相关心功能不全防治的循证医学证据，为肿瘤医生防治治疗相关心功能不全提供参考建议。

Abstract:

At present, cancer drug discovery is moving at lightning pace with increasing survival rates. It is imperative to commit to research on the cardiovascular side effects of all aspects of cancer therapy with a focus on prevention. Oncology trials often underrepresent the possibility of cardiovascular events in a "real world" population. With a large menu of biomarkers and imaging modalities available to the cardio oncologist, there continues to be no consensus regarding the best preventive strategy. It has become increasingly clear that early diagnosis and intervention leads to less late cardiotoxicity and fewer cardiac-related events. Finally, we outline the most current evidence based recommendations in this area, Provide suggestions for oncologists to optimize clinic preventional strategies within treatment-related cardiotoxicity.